Insights into severe asthma control as assessed by guidelines, pulmonologist, patient, and partner

Abstract

Introduction. The most recent guidelines on asthma management advocate a treatment strategy based on control of the disease rather than severity, a switch based on reported evidence. Aims. This observational, questionnaire-based study set out to investigate how control of the disease is assessed by the physician as well as the patient and his/her live-in partner and to compare these assessments with an assessment made according to the guidelines. Methods. In 169 patients with severe, persistent asthma on at least a high-dose inhaled corticosteroid plus an inhaled long-acting β₂-agonist, control of the disease was assessed by the pulmonologist, the patient, and the patient's live-in partner. These assessments were compared with an assessment based on the guidelines. Results. Both patients and partners tended to judge disease control as better than their pulmonologists who, in turn, estimated control as acceptable in 58% of their patients in whom the guidelines would advocate more aggressive treatment. The most common guidelines criteria defining inadequate control in the “uncontrolled” 87.4% of this population were “limitation of physical activity” (72.3%) and “FEV₁ ≤ 85% of personal best” (63.3%). Conclusions. To assess control in severe asthma, the patient's opinion is of limited value, as is that of their partners. Although a guidelines-based strategy has been shown to be effective in clinical trials conducted on large-scale populations in which mild or moderate disease is predominant, more aggressive treatment to achieve definitive control may not be appropriate in the 10% of asthma sufferers with severe disease; in everyday practice, lung specialists appear to implement such a strategy.

• asthma control
• uncontrolled asthma
• severe asthma
• difficult-to-treat asthma

Acknowledgments

We thank the physicians who kindly participated in this study. The study was conducted by Novartis Pharma who had a direct role in study design, data collection, analysis, and interpretation of data as well as writing of and decision to submit the manuscript.

Declaration of Interest

Mathieu Molimard is consultant for Novartis Pharma. Daniel Vervloet has no conflict of interest. Vincent Le Gros, Anne Ponthieux, and Isabelle Bourdeix are employees of Novartis Pharma.